Lupin Limited

Lupin Limited

Lupin Limited has informed the Exchange about a copy of Newspaper Publication relating to Annual General Meeting and e-voting related information.

Lupin Limited

Lupin Limited has been recognized as one of India's Best Employers in the Nation-Builders Category by Great Place To Work India 2026, ranking among the top 14 organizations nationally.

Lupin Limited

Lupin Limited has informed the Exchange regarding 'Business Responsibility and Sustainability Report of the Company for FY 2025-26'.

Lupin Limited

Lupin Limited has informed the Exchange regarding Notice of the Forty-Fourth Annual General Meeting of the Company and Integrated Report for FY 2025-26.

Lupin Limited

Lupin Limited has informed the Exchange about a copy of Newspaper Advertisement relating to Annual General Meeting, Record Date, and other related information.

Lupin Limited

Lupin Limited has announced the record date for the purpose of dividend payment as July 17, 2026, for a final dividend of ₹ 18 per equity share.

Lupin Limited

Lupin Limited has informed the Exchange regarding Intimation of the Forty-Fourth Annual General Meeting to be held on August 04, 2026, and record date for payment of final dividend of ₹ 18 per equity share.

Lupin Limited

Lupin Limited has informed the Exchange regarding the allotment of 2358 shares under the ESOP (Employee Stock Option Plan) to its employees and subsidiaries.

Lupin Limited

Lupin Limited has submitted a certificate under SEBI (Depositories and Participants) Regulations, 2018, confirming the acceptance or rejection of dematerialized securities and listing of securities on stock exchanges.

Lupin Limited

Lupin Limited has been named among the world's most sustainable companies by TIME and Statista, ranking 318th among 750 companies selected from over 5,000 of the world's largest and most influential organizations.

Lupin Limited

Lupin Limited has received an Establishment Inspection Report (EIR) from the US FDA for its Somerset facility with a satisfactory Voluntary Action Indicated (VAI) classification.

Lupin Limited

Lupin Limited has completed the acquisition of minority shareholding in Multicare Pharmaceuticals Philippines, Inc. (MPPI) and MPPI has completed the buy-back of 61,118 shares from two existing shareholders.

Lupin Limited

Lupin Limited has announced that the European Medicines Agency (EMA) has approved a change to the terms of marketing authorization for NaMuscla, a treatment for myotonia symptoms in non-dystrophic myotonic disorders, with new dosage strengths and expanded pediatric indication.

Lupin Limited

Lupin Limited has informed the Exchange regarding the grant of 65,251 stock options to its employees and subsidiaries, with an exercise price of ₹ 2.00 per option and a vesting period of three years.

Lupin Limited

Lupin Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015.

Lupin Limited

Lupin Limited has received tentative approval from the U.S. FDA for its Abbreviated New Drug Application for Enzalutamide Tablets, providing alternative dosing options for healthcare providers and patients.

Lupin Limited

Lupin Limited has announced the grant of 1,567,591 stock options to its employees and subsidiaries under the Lupin Employees Stock Option Scheme 2025. Each option provides the right to subscribe to one equity share at an exercise price of ₹2.00. These options will vest over a three-year period, commencing one year after the effective grant date of July 01, 2026, subject to specific performance conditions. This initiative aims to incentivize and retain key talent within the organization.